ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
CoQ10 reduces inflammasome activation in Fibromyalgia patients
Wednesday 31 July 2013
Editor's comment: Inflammasomes are multiprotein molecular complexes that sense a wide variety of pathogens and are key players in the inflammatory response. While inflammasomes are part of an important immune response that can protect the body, when there is overwhelming damage or infection, the ensuing inflammatory response can become chronic and injurious to the body. This type of response can be seen in a number of autoinflammatory and autoimmune disorders.
Other studies have demonstrated that mitochondrial dysfunction triggers activation of the NLRP3 inflammasome. This study found that treating fibromyalgia patients with CoQ10, which is known to support mitochondrial function, also reduced NLRP3 inflammasome activation.
NLRP3 Inflammasome is activated in Fibromyalgia: the effect of Coenzyme Q10.
By Mario D. Cordero, et al.
Aims: Fibromyalgia (FM) is a prevalent chronic pain syndrome characterized by generalized hyperalgesia associated with a wide spectrum of symptoms such as fatigue and joint stiffness. Diagnosis of FM is difficult due to the lack of reliable diagnostic biomarkers, while treatment is largely inadequate.
We have investigated the role of coenzyme Q10 (CoQ10) deficiency and mitochondrial dysfunction in inflammasome activation in blood cells from FM patients, and in vitro and in vivo CoQ10 deficiency models.
Innovations: These results show an important role for the NLRP3 inflammasome in the pathogenesis of FM, and the capacity of CoQ10 in the control of inflammasome.
Conclusions: These findings provide new insights into the pathogenesis of FM and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Source: Antioxidant & Redox Signaling, July 25, 2013. By Mario D. Cordero, Elisabet Alcocer-Gómez, Ognjen Culic, Angel M. Carrión, Manuel de Miguel, Eduardo Díaz-Parrado, Eva M. Perez-Villegas, Pedro Bullon, Maurizio Battino and José A. Sánchez-Alcázar. Dpto. Citología e Histología Normal y Patológica, Facultad de Medicina. Universidad de Sevilla, 41009 Sevilla-Spain, Avda. Sánchez-Pizjuán s/n , Sevilla, Spain, 41009.
The above originally appeared here.
blog comments powered by Disqus